Stock AnalizAbbott Laboratories (ABT) earnings for the quarter ended September 2026: EPS matches estimates
Abbott Laboratories reported results for the quarter ended September 2026 on October 21, 2026. Adjusted earnings per share came in at $1.42 against the analysts’ average forecast of $1.42.
Revenue for the quarter was $13.01 billion, up 14.5% from $11.37 billion in the same quarter a year earlier.
The market’s verdict: the stock fell 1.9% on the first trading day after the report.
The last four quarters
Abbott Laboratories has beaten the analysts’ EPS forecast in 2 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $1.42 | $1.42 | +0.0% | +14% | −1.9% |
| Jun 2026 | $1.31 | $1.28 | +2.6% | — | +12.8% |
| Mar 2026 | $1.15 | $1.15 | +0.3% | +8% | −4.7% |
| Dec 2025 | $1.50 | $1.49 | +0.3% | +4% | −11.0% |
What comes next
Analysts expect EPS of $1.64 for the next quarter on average and $5.52 for the fiscal year ending December 31, 2026.
The average analyst price target is $118.91, 10% above the current price of $108.52.
Valuation and score
Abbott Laboratories scores 1.8 out of 5 overall on Stock Analiz (weak), trades at a trailing P/E of about 40.3, and its intrinsic value under moderate assumptions is about 20% below the current market value. Full Abbott Laboratories analysis with 10 years of financials
Frequently asked questions
What was Abbott Laboratories’s EPS for the quarter ended September 2026?
$1.42 adjusted per share, against an analyst consensus of $1.42.
How much revenue did Abbott Laboratories report?
$13.01 billion, up 14.5% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.